Guanyl hydrazones are emerging as valuable, target-tunable functional groups. In particular, aryl guanyl hydrazones, owing to extensive conjugation with aromatic rings, exhibit lower pKa values compared to their aliphatic counterparts, so that, at physiological pH, a substantial proportion of them remains in a nonionized or partially protonated form, thereby increasing their lipophilicity and enhancing BBB permeability. Intriguingly, their tautomeric equilibria provide flexible charge allocation, adapting to binding site demands for protein and nucleic acid target species. Herein, (hetero)aromatic drugs, clinical candidates, leads and hits bearing one or more guanyl hydrazones are presented in terms of mechanism of action, in vitro and in vivo potency. Synthetic access to guanyl hydrazone-containing molecules, through complementary and simple routes, is briefly presented. Future trends for aryl guanyl hydrazones in CNS and PNS drug discovery are critically discussed.

Aryl Guanyl Hydrazones: A Viable Strategy for Designing BBB-Permeable, Neuroactive Compounds?

Donati G.;Mastrangelo E.;Milani Mario;Marinelli L.;
2025

Abstract

Guanyl hydrazones are emerging as valuable, target-tunable functional groups. In particular, aryl guanyl hydrazones, owing to extensive conjugation with aromatic rings, exhibit lower pKa values compared to their aliphatic counterparts, so that, at physiological pH, a substantial proportion of them remains in a nonionized or partially protonated form, thereby increasing their lipophilicity and enhancing BBB permeability. Intriguingly, their tautomeric equilibria provide flexible charge allocation, adapting to binding site demands for protein and nucleic acid target species. Herein, (hetero)aromatic drugs, clinical candidates, leads and hits bearing one or more guanyl hydrazones are presented in terms of mechanism of action, in vitro and in vivo potency. Synthetic access to guanyl hydrazone-containing molecules, through complementary and simple routes, is briefly presented. Future trends for aryl guanyl hydrazones in CNS and PNS drug discovery are critically discussed.
2025
Istituto di Biofisica - IBF - Sede Secondaria Milano
aryl guanyl hydrazones
BBB
bioavailability
NMR
nucleic acid binding
pK
a
rational drug design
tautomeric equilibria
File in questo prodotto:
File Dimensione Formato  
aryl-guanyl-hydrazones-a-viable-strategy-for-designing-bbb-permeable-neuroactive-compounds.pdf

accesso aperto

Licenza: Creative commons
Dimensione 3.5 MB
Formato Adobe PDF
3.5 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/559588
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact